spacer
home > epc > autumn 2002 > moving through clinical phases ii and iii
PUBLICATIONS
European Pharmaceutical Contractor

Moving Through Clinical Phases II and III

This article is not a step-by-step guide to the well-defined stages of clinical development, as there are plenty of excellent texts on the definitions of each phase and all the regulatory requirements and implications. However, it is useful to review the impact of the individuals involved in the team assembled to convert the project to a product.

So let's move beyond the mechanical activities to the thought processes at each stage, the considerations and implications of the decision-making at each step, and how these are communicated to everyone involved.

In an ideal world the end of Phase I is reached with all the preclinical data completed to add to the first human safety and tolerance data. The project is then clearly mapped out through the stages leading to marketing approval for the chosen indication(s), with all the timelines neatly illustrated by whatever project management software is used. And then reality kicks in...


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Philip Guard, Vice-President of European Operations at Clinimetrics Research Associates Inc

Philip Guard has been in the pharmaceutical and biotech industry for over 16 years. Four years as a practicing veterinarian was followed by four years at Glaxo Animal Health.

He then joined Cortecs, a UK biopharmaceutical company (now Provalis), where he established both the clinical research and the project management groups and developed them into directorates within the company. His direct experience in clinical research covers a broad spectrum including therapeutics, biologicals and diagnostics. Philip joined Clinimetrics in 1999.

spacer
Philip Guard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement